Zusammenfassung
Die ovariellen Keimstrang-Stromatumoren (OKST) umfassen eine faszinierende, heterogene Gruppe von Neoplasien mit einem breiten Spektrum klinischer und pathologischer Merkmale. Hierzu gehören neben gutartigen Tumoren auch solche mit malignem Potenzial.
Klinische Besonderheit erlangen diese Tumoren durch spezifische hyperöstrogene oder -androgene Symptomatik als Folge intratumoraler Produktion von Steroidhormonen. Die rein histologische Diagnosestellung ist aufgrund gelegentlich komplexer oder überlappender Merkmale anspruchsvoll und gelegentlich frustran. Zur Abgrenzung der OKST von keimstrangartigen anderen Ovarialtumoren hat sich die Verwendung eines Panels immunhistochemischer Keimstrangmarker (z. B. Inhibin-α, Calretinin) bewährt. In jüngerer Zeit sind molekulare Besonderheiten dieser Tumorgruppe erforscht worden, insbesondere wurden Mutationen von FOXL2 und DICER1 in bestimmten OKST beschrieben. Entsprechende Mutationsanalysen können bereits heute in besonderen Fällen diagnostisch hilfreich sein, auch werden sie womöglich einen Impuls für die zukünftige Klassifikation von OKST geben und sollten auf ihr Potenzial als Prognosefaktoren sowie im Rahmen neuer Therapieansätze überprüft werden.
In der vorliegenden Übersichtsarbeit werden die klinischen und histopathologischen Merkmale der adulten und juvenilen Granulosazelltumoren (AGCT und JGCT) sowie der Sertoli-Leydig-Zell-Tumoren (SLCT) als klinisch wichtigster, potenziell maligner Vertreter der OKST dargestellt und im Rahmen der aktuellen molekularen Forschungsergebnisse diskutiert. Ergänzend wird über aktuelle, möglicherweise ebenfalls für die zukünftige Klassifikation von OKST bedeutsame Ergebnisse zu den seltenen Gynandroblastomen (GAB) berichtet.
Abstract
Sex cord-stromal tumors of the ovary (SCSTO) comprise a heterogeneous and fascinating group of neoplasms with diverse clinicopathological features, including benign lesions as well as tumors with malignant potential. Clinically, SCSTO may be associated with hyperestrogenic or androgenic function as a result of steroid hormone production by the tumor cells.
Histological diagnosis may be challenging due to complex and sometimes overlapping morphological features of the various tumor types. A panel of immunohistochemical sex cord markers (e. g. inhibin-α, calretinin) has proven to be helpful in confirming the cellular lineage of SCSTO and differentiating them from other sex cord-like ovarian lesions. Recently, molecular analysis of SCSTO has led to the discovery of specific molecular events such as FOXL2 and DICER1 mutations. In selected diagnostically challenging cases, mutation analysis of FOXL2 and DICER1 may be helpful in the differential diagnosis. Molecular analysis is also expected to help advance the classification of SCSTO, and it may hold prognostic potential and form the basis for future type-specific therapies.
This review focuses on the clinicopathological as well as the molecular features of adult and juvenile granulosa cell tumors (AGCTs and JGCTs) as well as Sertoli-Leydig cell tumors (SLCTs), these being the most relevant lesions with malignant potential in the SCSTO category. In addition, recently published molecular findings among rare ovarian gynandroblastomas (GABs) are described, which may also impact the future classification of SCSTO.
Literatur
Aguirre P, Scully RE, DeLellis RA (1986) Ovarian heterologous Sertoli-Leydig cell tumors with gastrointestinal-type epithelium. An immunohistochemical analysis. Arch Pathol Lab Med 110:528–533
Akman L, Ertas IE, Gokcu M et al (2016) Ovarian sertoli-leydig cell tumors: A multicenter long-term clinicopathological analysis of 27 patients. J Cancer Res Ther 12:290–294
Al-Agha OM, Huwait HF, Chow C et al (2011) FOXL2 is a sensitive and specific marker for sex cord-stromal tumors of the ovary. Am J Surg Pathol 35:484–494
Anglesio MS, Wang Y, Yang W et al (2013) Cancer-associated somatic DICER1 hotspot mutations cause defective miRNA processing and reverse-strand expression bias to predominantly mature 3p strands through loss of 5p strand cleavage. J Pathol 229:400–409
Auguste A, Bessière L, Todeschini AL (2015) Molecular analyses of juvenile granulosa cell tumors bearing AKT1 mutations provide insights into tumor biology and therapeutic leads. Hum Mol Genet 2015(24):6687–6698
Bessière L, Todeschini AL, Auguste A et al (2015) A Hot-spot of In-frame Duplications Activates the Oncoprotein AKT1. Juv Granulosa Cell Tumors Ebiomedicine 2:421–431
Brown J, Brady WE, Schink J et al (2014) Efficacy and safety of bevacizumab in recurrent sex cord-stromal ovarian tumors: results of a phase 2 trial of the Gynecologic Oncology Group. Cancer 120:344–351
Caburet S, Anttonen M, Todeschini AL et al (2015) Combined comparative genomic hybridization and transcriptomic analyses of ovarian granulosa cell tumors point to novel candidate driver genes. BMC Cancer 15:251
Chivukula M, Hunt J, Carter G et al (2007) Recurrent gynandroblastoma of ovary – A case report: a molecular and immunohistochemical analysis. Int J Gynecol Pathol 26:30–33
Cocquet J, Pailhoux E, Jaubert F et al (2002) Evolution and expression of FOXL2. J Med Genet 39:916–921
Conlon N, Schultheis AM, Piscuoglio S et al (2015) A survey of DICER1 hotspot mutations in ovarian and testicular sex cord-stromal tumors. Mod Pathol 28:1603–1612
Crisponi L, Deiana M, Loi A et al (2001) The putative forkhead transcription factor FOXL2 is mutated in blepharophimosis/ptosis/epicanthus inversus syndrome. Nat Genet 27:159–166
D’Angelo E, Mozos A, Nakayama D et al (2011) Prognostic significance of FOXL2 mutation and mRNA expression in adult and juvenile granulosa cell tumors of the ovary. Mod Pathol 24:1360–1367
Deavers MT, Malpica A, Liu J et al (2003) Ovarian sex cord-stromal tumors: an immunohistochemical study including a comparison of calretinin and inhibin. Mod Pathol 16:584–590
Erdreich-Epstein A, Monforte HL, Lavey RS et al (2002) Successful multimodality therapy of recurrent multifocal juvenile granulosa cell tumor of the ovary. J Pediatr Hematol Oncol 24:229–233
Espinosa I, Gallardo A, D’Angelo E et al (2015) Simultaneous carcinomas of the breast and ovary: utility of Pax-8, WT-1, and GATA3 for distinguishing independent primary tumors from metastases. Int J Gynecol Pathol 34:257–265
Foulkes WD, Priest JR, Duchaine TF (2014) DICER1: mutations, microRNAs and mechanisms. Nat Rev Cancer 14:662–672
Goulvent T, Ray-Coquard I, Borel S et al (2016) DICER1 and FOXL2 mutations in ovarian sex cord-stromal tumours: a GINECO Group study. Histopathology 68:279–285
Heravi-Moussavi A, Anglesio MS, Cheng SW (2012) Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers. N Engl J Med 366:234–242
Kalfa N, Ecochard A, Patte C et al (2006) Activating mutations of the stimulatory g protein in juvenile ovarian granulosa cell tumors: a new prognostic factor? J Clin Endocrinol Metab 91:1842–1847
Karnezis AN, Wang Y, Keul J et al (2019) DICER1 and FOXL2 mutation status correlates with clinicopathologic features in ovarian Sertoli-Leydig cell tumors. Am J Surg Pathol, accepted for publication
Kato N, Kusumi T, Kamataki A et al (2017) DICER1 hotspot mutations in ovarian Sertoli-Leydig cell tumors: a potential association with androgenic effects. Hum Pathol 59:41–47
Kim MS, Hur SY, Yoo NJ, Lee SH (2010) Mutational analysis of FOXL2 codon 134 in granulosa cell tumour of ovary and other human cancers. J Pathol 221:147–152
Kim MS, Lee SH, Yoo NJ et al (2013) DICER1 exons 25 and 26 mutations are rare in common human tumours besides Sertoli-Leydig cell tumour. Histopathology 63:436–438
de Kock L, Terzic T, McCluggage WG et al (2017) DICER1 Mutations Are Consistently Present in Moderately and Poorly Differentiated Sertoli-Leydig Cell Tumors. Am J Surg Pathol 41:1178–1187
Kommoss F, Oliva E, Bhan AK, Young RH, Scully RE (1998) Inhibin expression in ovarian tumors and tumor-like lesions: an immunohistochemical study. Mod Pathol 11:656–664
Kommoss F, Schmidt D (2007) Immunohistochemical sex cord markers. Description and use in the differential diagnosis of ovarian tumors. Pathologe 28:187–194
Kommoss S, Anglesio MS, Mackenzie R et al (2013) FOXL2 molecular testing in ovarian neoplasms: diagnostic approach and procedural guidelines. Mod Pathol 26:860–867
Kommoss S, Gilks CB, Penzel R et al (2014) A current perspective on the pathological assessment of FOXL2 in adult-type granulosa cell tumours of the ovary. Histopathology 64:380–388
Kurman RJ, Carcangiu ML, Herrington CS, Young RH (Hrsg) (2014) WHO Classification of Tumours of Female Reproductive Organs. International Agency for Research on Cancer, Lyon
Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) Therapie und Nachsorge maligner Ovarialtumoren, Langversion 1.0, AWMF Registrierungsnummer: 032-035OL. http://leitlinienprogramm-onkologie.de/Leitlinien.7.0.html
Lim D, Oliva E (2018) Ovarian sex cord-stromal tumours: an update in recent molecular advances. Pathology 50:178–189
Lin YS, Eng HL, Jan YJ et al (2005) Molecular cytogenetics of ovarian granulosa cell tumors by comparative genomic hybridization. Gynecol Oncol 97:68–73
Mayr D, Kaltz-Wittmer C, Arbogast S et al (2002) Characteristic pattern of genetic aberrations in ovarian granulosa cell tumors. Mod Pathol 15:951–957
McConechy MK, Färkkilä A, Horlings HM et al (2016) Molecularly Defined Adult Granulosa Cell Tumor of the Ovary: The Clinical Phenotype. J Natl Cancer Inst 108(11):13
McCluggage WG, Young RH (2005) Immunohistochemistry as a diagnostic aid in the evaluation of ovarian tumors. Semin Diagn Pathol 22:3–32
van Meurs HS, van Lonkhuijzen LR et al (2014) Hormone therapy in ovarian granulosa cell tumors: a systematic review. Gynecol Oncol 134:196–205
Moh M, Krings G, Ates D et al (2016) SATB2 Expression Distinguishes Ovarian Metastases of Colorectal and Appendiceal Origin From Primary Ovarian Tumors of Mucinous or Endometrioid Type. Am J Surg Pathol 40:419–432
Movahedi-Lankarani S, Kurman RJ (2002) Calretinin, a more sensitive but less specific marker than alpha-inhibin for ovarian sex cord-stromal neoplasms: an immunohistochemical study of 215 cases. Am J Surg Pathol 26:1477–1483
Nolan A, Joseph NM, Sangoi AR et al (2017) FOXL2 Mutation Status in Granulosa Theca Cell Tumors of the Ovary. Int J Gynecol Pathol 36:568–574
Oost EE, Charles A, Choong CS et al (2015) Ovarian sex cord-stromal tumors in patients with probable or confirmed germline DICER1 mutations. Int J Gynecol Pathol 34:266–274
Oparka R, Cassidy A, Reilly S et al (2012) The C134W (402 C〉G) FOXL2 mutation is absent in ovarian gynandroblastoma: insights into the genesis of an unusual tumour. Histopathology 60:838–842
Park M, Shin E, Won M et al (2010) FOXL2 interacts with steroidogenic factor-1 (SF-1) and represses SF-1-induced CYP17 transcription in granulosa cells. Mol Endocrinol 24:1024–1036
Prat J, Young RH, Scully RE (1982) Ovarian Sertoli-Leydig cell tumors with heterologous elements. II. Cartilage and skeletal muscle: a clinicopathologic analysis of twelve cases. Cancer 50:2465–2475
Rabban JT, Zaloudek CJ (2013) A practical approach to immunohistochemical diagnosis of ovarian germ cell tumours and sex cord-stromal tumours. Histopathology 62:71–88
Rosario R, Wilson M, Cheng WT et al (2013) Adult granulosa cell tumours (GCT): clinicopathological outcomes including FOXL2 mutational status and expression. Gynecol Oncol 131:325–329
Roth LM, Slayton RE, Brady LW et al (1985) Retiform differentiation in ovarian Sertoli-Leydig cell tumors. A clinicopathologic study of six cases from a Gynecologic Oncology Group study. Cancer 55:1093–1098
Schmidt D, Ovitt CE, Anlag K et al (2004) The murine winged-helix transcription factor Foxl2 is required for granulosa cell differentiation and ovary maintenance. Development 131:933–942
Schultz KA, Pacheco MC, Yang J et al (2011) Ovarian sex cord-stromal tumors, pleuropulmonary blastoma and DICER1 mutations: a report from the International Pleuropulmonary Blastoma Registry. Gynecol Oncol 122:246–250
Schultz KAP, Harris AK, Finch M et al (2017) DICER1-related Sertoli-Leydig cell tumor and gynandroblastoma: Clinical and genetic findings from the International Ovarian and Testicular Stromal Tumor Registry. Gynecol Oncol 147:521–527
Shah SP, Köbel M, Senz J et al (2009) Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med 360:2719–2729
Sigismondi C, Gadducci A, Lorusso D et al (2012) Ovarian Sertoli-Leydig cell tumors. A retrospective MITO study. Gynecol Oncol 125:673–676
Slade I, Bacchelli C, Davies H et al (2011) DICER1 syndrome: clarifying the diagnosis, clinical features and management implications of a pleiotropic tumour predisposition syndrome. J Med Genet 48:273–278
Staebler A, Kommoss F (2013) Ovarialtumoren IV. LS195 T 300 20100515. Int Akademie Für Pathol, 115–156
Takeda A, Watanabe K, Hayashi S et al (2017) Gynandroblastoma with a Juvenile Granulosa Cell Component in an Adolescent: Case Report and Literature Review. J Pediatr Adolesc Gynecol 30:251–255
Talerman A (1987) Ovarian Sertoli-Leydig cell tumor (androblastoma) with retiform pattern. A clinicopathologic study. Cancer 60:3056–3064
Tanaka Y, Sasaki Y, Nishihira H, Izawa T, Nishi T (1992) Ovarian juvenile granulosa cell tumor associated with Maffucci’s syndrome. Am J Clin Pathol 97:523–527
Vassal G, Flamant F, Caillaud JM et al (1988) Juvenile granulosa cell tumor of the ovary in children: a clinical study of 15 cases. J Clin Oncol 6:990–995
Vaz RM, Turner C (1986) Ollier disease (enchondromatosis) associated with ovarian juvenile granulosa cell tumor and precocious pseudopuberty. J Pediatr 108:945–947
Wang Y, Karnezis AN, Magrill J et al (2018) DICER1 hot-spot mutations in ovarian gynandroblastoma. Histopathology 73:306–313
Witkowski L, Mattina J, Schönberger S et al (2013) DICER1 hotspot mutations in non-epithelial gonadal tumours. Br J Cancer 109:2744–2750
Young RH, Prat J, Scully RE (1982) Ovarian Sertoli-Leydig cell tumors with heterologous elements. I. Gastrointestinal epithelium and carcinoid: a clinicopathologic analysis of thirty-six cases. Cancer 50:2448–2456
Young RH, Scully RE (1983) Ovarian Sertoli-Leydig cell tumors with a retiform pattern: a problem in histopathologic diagnosis. A report of 25 cases. Am J Surg Pathol 7:755–771
Young RH, Dickersin GR, Scully RE (1984) Juvenile granulosa cell tumor of the ovary. A clinicopathological analysis of 125 cases. Am J Surg Pathol 8:575–596
Young RH, Perez-Atayde AR, Scully RE (1984) Ovarian Sertoli-Leydig cell tumor with retiform and heterologous components. Report of a case with hepatocytic differentiation and elevated serum alpha-fetoprotein. Am J Surg Pathol 8:709–718
Young RH, Scully RE (1985) Ovarian Sertoli-Leydig cell tumors. A clinicopathological analysis of 207 cases. Am J Surg Pathol 9:543–569
Zaloudek C, Norris HJ (1982) Granulosa tumors of the ovary in children: a clinical and pathologic study of 32 cases. Am J Surg Pathol 6:503–512
Zaloudek C, Norris HJ (1984) Sertoli-Leydig tumors of the ovary. A clinicopathologic study of 64 intermediate and poorly differentiated neoplasms. Am J Surg Pathol 8:405–418
Zhao C, Vinh TN, McManus K et al (2009) Identification of the most sensitive and robust immunohistochemical markers in different categories of ovarian sex cord-stromal tumors. Am J Surg Pathol 33:354–366
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
F. Kommoss und H.-A. Lehr geben an, dass kein Interessenkonflikt besteht.
Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.
Additional information
Schwerpunktherausgeber
S. F. Lax, Graz
Rights and permissions
About this article
Cite this article
Kommoss, F., Lehr, HA. Keimstrang-Stromatumoren des Ovars. Pathologe 40, 61–72 (2019). https://doi.org/10.1007/s00292-018-0562-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00292-018-0562-3
Schlüsselwörter
- Granulosazelltumor
- Gynandroblastom
- Humanes DICER1-Protein
- Forkhead-Box-Protein L2
- Sertoli-Leydig-Zell-Tumor